{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": 0.7702236, "regularMarketPrice": 1.57, "exchange": "FRA", "shortName": "APTEVO THERAP.INC.DL-,001", "longName": "Aptevo Therapeutics Inc.", "messageBoardId": "finmb_331280020", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "marketState": "REGULAR", "esgPopulated": false, "priceEpsCurrentYear": -0.27738518, "sharesOutstanding": 7239470, "bookValue": 2.78, "fiftyDayAverage": 1.72877, "fiftyDayAverageChange": -0.15876997, "fiftyDayAverageChangePercent": -0.09183984, "twoHundredDayAverage": 2.584405, "twoHundredDayAverageChange": -1.0144049, "twoHundredDayAverageChangePercent": -0.39251006, "marketCap": 11457656, "forwardPE": -0.3030888, "priceToBook": 0.5647482, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1471500000000, "priceHint": 4, "regularMarketChange": 0.012000084, "regularMarketTime": 1683892036, "regularMarketDayHigh": 1.57, "regularMarketDayRange": "1.524 - 1.57", "regularMarketDayLow": 1.524, "regularMarketVolume": 800, "regularMarketPreviousClose": 1.558, "bid": 1.57, "ask": 1.624, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.524, "averageDailyVolume3Month": 190, "averageDailyVolume10Day": 80, "fiftyTwoWeekLowChange": 0.100000024, "fiftyTwoWeekLowChangePercent": 0.06802723, "fiftyTwoWeekRange": "1.47 - 6.134", "fiftyTwoWeekHighChange": -4.5639997, "fiftyTwoWeekHighChangePercent": -0.74404955, "fiftyTwoWeekLow": 1.47, "fiftyTwoWeekHigh": 6.134, "earningsTimestamp": 1683808200, "earningsTimestampStart": 1691584200, "earningsTimestampEnd": 1692016200, "trailingAnnualDividendRate": 0.0, "trailingPE": 1.2460318, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 1.26, "epsForward": -5.18, "epsCurrentYear": -5.66, "symbol": "AP8N.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "2401 4th Avenue", "address2": "Suite 1050", "city": "Seattle", "state": "WA", "zip": "98121", "country": "United States", "phone": "206 838 0500", "fax": "206 838 0503", "website": "https://www.aptevotherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 45, "companyOfficers": [{"maxAge": 1, "name": "Mr. Marvin L. White", "age": 60, "title": "Pres, CEO & Director", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 892861, "fmt": "892.86k", "longFmt": "892,861"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jeffrey G. Lamothe CA", "age": 56, "title": "Exec. VP & COO", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 691369, "fmt": "691.37k", "longFmt": "691,369"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. SoYoung  Kwon J.D., LL.M.", "title": "Sr. VP, Gen. Counsel, Bus. Devel. & Corp. Affairs", "fiscalYear": 2022, "totalPay": {"raw": 588033, "fmt": "588.03k", "longFmt": "588,033"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Daphne L. Taylor", "age": 56, "title": "Sr. VP & CFO", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jane A. Gross Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1957, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Fatih M. Uckun M.D., Ph.D.", "title": "Chief Clinical Advisor & Consultant", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dirk  Huebner M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}